Aradigm Corporation (ARDM) was a company that focused on the development and commercialization of drugs for the treatment of severe respiratory diseases. The company was headquartered in Hayward, California, and was founded in 1991.
ARDM's lead product candidate was an inhaled antibiotic called Linhaliq (previously known as Pulmaquin), which was being developed for the treatment of non-cystic fibrosis bronchiectasis (NCFB). NCFB is a chronic respiratory disease that is characterized by inflammation and the buildup of mucus in the airways, leading to recurrent infections and progressive lung damage.
Linhaliq was designed to be delivered directly to the lungs via an inhaler, allowing for high concentrations of the antibiotic to be delivered directly to the site of infection. The drug had shown promise in clinical trials, with positive results in improving lung function and reducing exacerbations.
However, in 2018, Aradigm Corporation filed for bankruptcy and subsequently sold the rights to Linhaliq to a consortium of investors.
|
